Document ID: chunk:federal_register_of_legislation:F2023L01747:schedule:1:p16
Version: federal_register_of_legislation:F2023L01747
Segment Type: schedule
Provision Reference: sch 1 (pt 16/31)
Character Range: 50859–54174

NP  C6147 C6191     2  5  1

     [95]               Schedule 1, Part 1, entry for Triglycerides - medium chain, formula
     omit:
   Sachets containing oral powder 16 g, 30 (MCT Pro-Cal)  Oral     MCT Pro-Cal  VF  MP NP  C6136 C6156 C6165 C6173 C6192     4  5  1

     [96]               Schedule 1, Part 1, entry for Ustekinumab in the form Injection 90 mg in 1 mL single use pre-filled syringe [Maximum Quantity: 1; Number of Repeats: 0]
         (a)           insert in numerical order in the column headed "Circumstances": C14758 C14787 C14801 C14802 C14806
         (b)           insert in numerical order in the column headed "Purposes": P14758 P14787 P14801

     [97]               Schedule 1, Part 1, entry for Ustekinumab in the form Injection 90 mg in 1 mL single use pre-filled syringe [Maximum Quantity: 1; Number of Repeats: 1]
         (a)           insert in numerical order in the column headed "Circumstances": C14758 C14787 C14801 C14802 C14806
         (b)           insert in numerical order in the column headed "Purposes": P14802 P14806

     [98]               Schedule 1, Part 1, entry for Varenicline in the form Tablet 1 mg (as tartrate)
     insert in the column headed "Schedule Equivalent" (all instances): a

     [99]               Schedule 1, Part 1, entry for Varenicline
     omit:
   Tablet 1 mg (as tartrate) (s19A)  Oral     APO-Varenicline (Canada)  XT  MP NP  C6885 C7483  P6885  56   2  56
                                                                            MP NP  C6885 C7483  P7483  112  0  56

     [100]           Schedule 1, Part 1, entry for Venetoclax in the form Pack containing 14 tablets venetoclax 10 mg and 7 tablets venetoclax 50 mg and 7 tablets venetoclax 100 mg and 14 tablets venetoclax 100 mg
         (a)           omit from the column headed "Circumstances": C14325
         (b)           insert in numerical order in the column headed "Circumstances": C14776

     [101]           Schedule 1, Part 1, entry for Zanubrutinib
         (a)           omit from the column headed "Circumstances": C14344
         (b)           insert in numerical order in the column headed "Circumstances": C14788

     [102]           Schedule 1, Part 1, entry for Ziprasidone in each of the forms: Capsule 20 mg (as hydrochloride); Capsule 40 mg (as hydrochloride); Capsule 60 mg (as hydrochloride); and Capsule 80 mg (as hydrochloride)
     omit:
         a  APO-Ziprasidone  TX  MP NP  C4246 C5742     60  5  60

     [103]           Schedule 1, Part 2, omit entry for Essential amino acids formula with vitamins and minerals

     [104]           Schedule 1, Part 2, after entry for Filgrastim in the form Injection 480 micrograms in 1.6 mL
                           insert:
Hydralazine  Tablet containing hydralazine hydrochloride 25 mg  Oral     Alphapress 25  AF  MP NP        200  2  100
             Tablet containing hydralazine hydrochloride 50 mg  Oral     Alphapress 50  AF  MP NP        200  2  100

     [105]           Schedule 1, Part 2, after entry for Sterculia with frangula bark in the form Granules 620 mg-80 mg per g, 500 g [Maximum Quantity: 1; Number of Repeats: 3]
                           insert:
Triglycerides, medium chain            Oral liquid 225 mL, 15 (K.Quik)                        Oral     K.Quik                    VF